The current ESC guidelines recommend using sodium-glucose transporter 2 (SGLT2) inhibitors for managing HF patients, regardless of left ventricular ejection fraction (LVEF), once the patient’s condition is stable [38]. Here, SLC5A2 is linked to hydrops fetalis.